肺癌联合免疫治疗反应的基因组特征。
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
机构信息
Department of Medical Oncology/Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland.
Department of Medical Oncology, University Hospital of Lausanne (CHUV), 1011 Lausanne, Switzerland.
出版信息
Cancer Cell. 2018 May 14;33(5):791-793. doi: 10.1016/j.ccell.2018.04.005.
PMID:29763618
Abstract
In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.
摘要
在本期《癌细胞》杂志中，Hellmann 等人在两项临床试验中描述了肿瘤突变负担作为独立预测标志物的重要性，该标志物可预测转移性非小细胞肺癌和复发性小细胞肺癌患者一线使用纳武利尤单抗联合伊匹单抗治疗的结局。
Zotero 插件